Natalie E. Allen
Jie Zhang
Charles N. J. McGhee*- Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Aim: To provide a comprehensive literature review on the perceived correlation between COVID-19 vaccination and corneal allograft rejection, and to characterize risk factors, time course, graft outcomes and proposed immunological basis.
Methods: A literature review was conducted in August 2023 using 4 electronic databases: PubMed, EMBASE, MEDLINE and Scopus. Articles were sourced using key words associated with COVID-19 vaccination and corneal graft. All articles were screened for relevance by abstract review. Duplicates and articles related to COVID-19 infection were excluded. No time limits were set. Additional literature searches regarding cause of corneal graft rejection, rates of graft rejection associated with other vaccines and the cellular mechanism of rejection were also performed.
Results: 262 articles were identified from the literature search. 37 papers were included in the analysis based on defined inclusion criteria. This consisted of systematic reviews (n=6), review articles (n=5), retrospective studies (n=3), case series (n=8), letter to the editor (n=1) and case reports (n= 14). The majority of reported allograft rejections were in penetrating keratoplasties. Risk factors for COVID-19 vaccination associated rejection were previous allograft rejection episodes, repeat grafts and penetrating keratoplasty. Most reported rejection episodes were mild and resolved with treatment. Notably, several studies reported nil increase in corneal allograft rejection episodes over the COVID-19 vaccination period. Rejection episodes are associated with a broad spectrum of other vaccines and the complete pathophysiology is undetermined.
Conclusion: Corneal allograft rejection appears to be a rare complication of COVID-19 vaccination most frequently observed in high-risk corneal transplants. The true extent of this correlation remains controversial; however, clinician awareness of this risk is essential to its mitigation. Patient counselling around symptom monitoring following vaccination and discussion around topical steroid prophylaxis may be prudent.
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious virus that swept across the globe in December 2019 resulting in the coronavirus disease (COVID-19) pandemic (Wiersinga et al., 2020). Estimated to have resulted in excess deaths of 14.8 million globally, the pandemic was declared to no longer be a “global health emergency” by the World Health Organization (WHO) on May 6th 2023 (Msemburi et al., 2023). This was due in part to the development and distribution of recombinant mRNA vaccines, of which over 13 billion doses have been administered globally by July 2023 (Mathieu et al., 2020).
Corneal allograft transplantation is an end-stage treatment for several corneal pathologies (Kim et al., 2016; Alio et al., 2021; Yin, 2021). The terms “corneal transplantation or corneal graft” refer to several different operations involving corneal allograft tissue of varying layers and thickness. Penetrating keratoplasty (PK) involves transplantation of all five key layers i.e. from anterior to posterior, the corneal epithelium, Bowman’s layer, corneal stroma, Descemet’s membrane and endothelium. Deep anterior lamellar keratoplasty (DALK) typically involves transplantation of the corneal epithelium and full-thickness stroma without the highly immunogenic endothelium (Crawford et al., 2013; Yin, 2021).
Descemet’s stripping (automated) endothelial keratoplasty (DS(A)EK) is a lamellar procedure that utilizes donor tissue comprising a thin layer of deep corneal stroma plus the subjacent Descemet’s membrane and endothelium. Descemet’s membrane endothelial keratoplasty (DMEK) utilizes donor tissue that includes Descemet’s membrane and the endothelium.
Corneal transplantation is arguably the most successful tissue transplantation due to its (relative) immune privilege (Niederkorn, 2006; Maharana et al., 2023). It does not require HLA matching or routine systemic immunosuppression due to lymphangiogenic and hemangiogenic privilege (Hori et al., 2019; Maharana et al., 2023). The cornea has no blood vessels or lymphatics, with inhibitory collagens within the corneal stroma which inhibit blood vessel growth. The anatomy of the limbus impedes vascularization of the adjacent cornea (Bron et al., 1997). Collagen fibers I and V are integral to maintaining corneal clarity and impede the growth of vessels into the corneal stroma. The limbal arcade remains 1-5mm outside of the corneal limbus and has no smooth muscle but contains actin filaments under normal physiological conditions. Under hypoxic conditions, these actin filaments are impeded by nitric oxide released by the vascular endothelium, causing vascular dilation and subsequent neovascularization (Hori et al., 2019). The corneal epithelium also expresses several factors such as VEGF receptor3 (VEGFR-3) and TNF-related apoptosis-inducing ligand (TRAIL) which are angiostatic factors (Hori et al., 2019; Maharana et al., 2023). This immune privilege is variable between layers of the cornea, with the epithelium being less immune privileged than the endothelium. This explains the lower rates of graft rejection in DSAEKs and DMEKs (9%) compared with PKs (21%) (Zhang et al., 2019; Yin, 2021; Maharana et al., 2023).
Corneal allograft rejection describes a pattern of symptoms and clinical signs indicating that the host immune system is responding to the allograft, and is the leading cause of corneal graft failure (Panda et al., 2007). The most common indication for repeat corneal transplantation is corneal endothelial failure (Lu et al., 2019). Rejection episodes occasionally may be relatively asymptomatic in mild cases but are more typically characterized by several symptoms including photophobia, ocular redness (often circumcorneal), blurred vision, discomfort and epiphora. By definition at least one of the following clinical signs should be present; epithelial rejection line, sub-epithelial infiltrates (Krachmer spots), stromal oedema, and anterior chamber inflammation with keratic precipitates on the endothelium and/or an endothelial rejection line (Khodadoust’s line). This process typically occurs after 2 weeks or longer postoperatively in primary allograft rejection and the changes are usually limited to the graft tissue (Panda et al., 2007; Alio et al., 2021).
It is postulated that vaccines alter the immune privilege of the eye. Surgery induces expression of major histocompatibility complex class-Ii expression in the antigen presenting cells (APCs) of the cornea, namely, corneal dendritic cells (cDCs), and induces the expression of costimulatory molecules. cDCs enter a mature state. Both donor and/or host cDCs in the central cornea can migrate to the host peripheral cornea, then to the lymph nodes. T cells within lymph nodes then induce an immune response involving induction of cytotoxic T cells and proinflammatory IgG antibody production within B cells. This leads to a Delayed Type Hypersensitivity response, which then causes graft rejection. This is modulated by two active mechanisms: anterior chamber-associated immune deviation (ACAID) and the intraocular immunosuppressive microenvironment (Niederkorn, 2007; Maharana et al., 2023). ACAID is induced systemic tolerance to alloantigens within the anterior chamber. When antigens arrive in the anterior chamber, antigen-bearing antigen-presenting cells (APCs) travel via the trabecular meshwork to the spleen, which produces TGF-beta, TSP-1, and MIP-2. These factors attract natural killer T cells (NKT cells), which in turn attract marginal zone B cells (Maharana et al., 2023). These activities create an environment in which responding T cells differentiate into CD4+ T regulatory cells (Tregs), which inhibit the Delayed Type Hypersensitivity response. The immunosuppressive microenvironment involves several soluble factors within the anterior chamber and cell surface molecules within the cornea, iris and ciliary body which act to hinder the usual systemic immune response to pathogens. These include Calcitonin gene-related peptide which suppresses macrophage activity, and Vasoactive intestinal peptide which suppresses T cells (Gonzalez-Rey et al., 2007; Hori et al., 2019).
Vaccination against various infectious pathologies may compromise corneal immune privilege and is anecdotally associated with corneal allograft rejection (Steinemann et al., 1988; Streilein, 2003; Melo-González et al., 2021; Dugan and Mian, 2022). Recent case reports and retrospective case series have described links between COVID-19 vaccination and ocular pathology including corneal graft rejection (Abousy et al., 2021; Crnej et al., 2021; Al-Dwairi et al., 2022). Therefore, this literature review aims to provide an in-depth analysis of the perceived correlation between COVID-19 vaccination and corneal allograft rejection, supplemented by the characteristics, time course, clinical outcomes and consideration of the underlying immunological basis.
Method
We conducted a literature search in August 2023 using 4 electronic databases: MEDLINE, SCOPUS, PubMed and EMBASE. We performed a search of all English language literature using the following terms “Covid-19, coronavirus-19, SARS-CoV-2, 2019-nCoV, vaccine, vaccination, immunization, immunization, cornea, corneal graft, keratoplasty, corneal transplantation, corneal tissue, DSAEK, DMEK, PKP” and their synonyms, matching to MeSH headings when searching in Pubmed. No time range limits were set for the literature search. All case reports, case series, systematic reviews, narrative reviews and meta-analyses were included. Correspondence with no patient data was excluded. The references of the remaining publications were also reviewed to identify relevant literature. The full texts of all remaining studies were screened as outlined in Figure 1, and if they contained COVID-19 vaccination and corneal grafts, they were included. Studies of COVID-19 infection alone and corneal allograft rejection alone were excluded. Studies of other types of vaccination and corneal allograft rejection were excluded from the analysis but read for the purpose of better understanding the potential immunological mechanisms behind rejection.
Figure 1 Summary of literature search.
Results
Across all four databases, 262 results articles were identified. Of these, 48 were excluded as duplicates, 6 were excluded due to publication type and 170 were excluded due to relevance. This left 37 papers on COVID-19 vaccination and corneal allograft rejection in the literature. This included 6 systematic reviews, 5 review articles, 3 retrospective studies, 8 case series, 14 case reports and one letter to the editor. There were numerous different variations of COVID-19 vaccination described. Within the non-review papers mRNA-1273 (Moderna) was described 7 times, AZD1222 (Oxford-AstraZeneca) was described 10 times, BNT162b2 (Pfizer) was described 15 times, BBIBP-CorV (Sinopharm) was described 8 times, Sinovac was described once and BBV152 (Covaxin) was described once. This is summarized in Table 1.
Table 1 COVID-19 and Corneal Graft Rejection.
A total of 44 eyes in 42 patients were included (mean age 56.9 with 43.9% female). Of those 27 eyes had penetrating keratoplasties, 6 eyes had DSAEKs, 7 eyes had DMEKs, 2 had DALKs, one had a combined penetrating keratoplasty and keratolimbal allograft (KLAL), and one had a femtosecond laser-assisted penetrating keratoplasty (FLEK). A large proportion of described cases (47.6%, n=20 patients) occurred in individuals with established risk factors for rejection. These include young patients, bilateral transplants, previous graft rejection and a high level of corneal neo-vascularization (Panda et al., 2007). Fourteen patients had previous rejection episodes (32.6%).
The time between vaccination and rejection episode varied from one day to 117 days post-surgery [Figure 2] with a mean of 16.1 days and a median of 11 days [IQR 7 – 14]. No difference was observed in time to rejection by gender (p=0.928) but there was a trend towards faster time to rejection reported in older subjects (p=0.069) and a shorter time from vaccination to rejection was observed in those with risk factors for graft rejection (p=0.030). No difference was observed in the reported time to rejection following vaccination by vaccine type (p=0.5714) or by graft type (p=0.7969). Rejection episodes were treated through a variety of means, mostly topical steroids such as prednisolone or dexamethasone. In 26.2% of cases (n=11) patients were also treated with systemic steroids. Most (79.6%, N=35 eyes) acute rejection episodes resolved with treatment.
Figure 2 Time from vaccination to rejection episode.
The majority of the published literature on COVID-19 vaccination and corneal graft rejection are case reports and small case series. There are no corneal graft and COVID-19 vaccination-specific meta-analyses published to date, but there is a large meta-analysis on organ rejection as a whole showing corneal graft rejection is the most widely reported type of tissue rejection following COVID-19 vaccination in the literature (n=38), accounting for 67.8% of all “organ” rejections (Alhumaid et al., 2022). There are distinct differences between the pathogenesis of (solid organ) rejection and tissue rejection. Solid organ rejection is cell and antibody-mediated whilst tissue rejection is purely cell-mediated, however, the prevalence of both in relation to COVID-19 vaccination suggests an underlying alteration to systemic immunogenicity (Streilein, 2003; Yin, 2021).
Several systematic reviews specific to corneal allograft rejection have been published. The rate of corneal allograft rejection secondary to COVID-19 vaccination is estimated at 0.004 per million, calculated by dividing the number of events by the number of doses (Moura-Coelho et al., 2023). Despite the inferred relation between the vaccine and rejection due to temporal association, within the systematic reviews which discussed corneal allograft rejection following COVID-19 vaccination, none found sufficient evidence to definitively conclude causation (Lee and Huang, 2021; Fujio et al., 2022; Huang et al., 2022; Kumari et al., 2022; Wang et al., 2022; Kuziez et al., 2023; Moura-Coelho et al., 2023). There is significantly more published literature on COVID-19 vaccination and corneal allograft rejection than any other type of vaccination, but the systematic reviews deduce this is likely confounded by the profound public interest in the COVID-19 vaccination, following the global pandemic, encouraging publication (Kuziez et al., 2023; Moura-Coelho et al., 2023).
A large retrospective multi-center study of 471 cases of corneal graft rejection between January 2018 and March 2022 found no difference between rates of corneal graft rejection before COVID-19 and after the introduction of the COVID-19 vaccination (Roberts et al., 2022). This involved a retrospective review of presentations with corneal graft rejection over the study period. The numbers of rejections after the introduction of the COVID-19 vaccination program were compared with the numbers before vaccination and also prior to the pandemic. There was no attempt to link individual graft rejection episodes to the COVID-19 vaccination per se. Similarly, an Italian study of 77 cases of rejection amongst 2062 patients who underwent corneal transplants from January 2018 to December 2021 found no increase in rejection rates following the vaccine scheme implementation in 2021 (Busin et al., 2022). This paper utilized both gross corneal graft rejection numbers and linked the timing of vaccination to a rejection episode, having only one case of rejection out of 77 which occurred within 60 days of receiving a COVID-19 vaccination.
Discussion
High quality data on the side effects of COVID-19 vaccination is essential as new variants continue to develop and more individuals are immunized (Barouch, 2022). The current literature linking COVID-19 vaccination to corneal transplant rejection is weak, with numbers too small for statistical significance or definitive conclusions. The vast majority of reported literature is individual case reports or case series. Within the reported cases, the intense scrutiny surrounding the vaccine has likely raised suspicion of causation rather than correlation. It is very challenging to ascertain whether a corneal allograft rejection is directly secondary to the COVID-19 vaccination. With around half of cases reported already at baseline high risk of rejection, it is likely some cases were destined for rejection with or without the vaccination. Some papers reported cases as sequelae of the COVID-19 vaccine when the rejection was as long as 117 days post-immunization (Ghiasian et al., 2023). There is no consensus on a sensible interval between vaccine and rejection, and all of these cases were included in our analysis. Further research may benefit from an exclusion criteria of greater than 60 days.
The three larger retrospective studies showed no statistically significant increase in corneal graft rejection with the introduction of the COVID-19 vaccination However, data collection challenges during the pandemic period leave these open for significant confounding issues. During the height of the pandemic, all of the countries involved in these studies experienced some form of lockdown, likely hindering presentation to health services. These studies were all retrospective and relied on accurate clinical coding for their diagnosis of corneal graft rejection which may result in incomplete data. The clinical demographics of the individuals were also not discussed, which is suboptimal as the pre-existing risk factors of a patient play a profound role in the integrity of their immune privilege and hence their likelihood to reject (Streilein, 2003; Maharana et al., 2023).
The likelihood of developing a rejection following COVID-19 vaccination appears to be correlated to a patient’s underlying risk factors. In 47.3% of cases, patients had established risk factors for rejection and 32.2% had previous rejection episodes. This is likely a result of loss of the immune privilege of the cornea in any circumstance outside of normal physiological conditions, including trauma, inflammation, neovascularization and infection (Niederkorn, 2007). Hence almost all patients undergoing corneal transplantation have compromise of their corneal immune privilege and the potential for rejection. The mechanism for this is widely believed to be CD4+ T cell-mediated via an afferent and effector arm (Niederkorn, 2006; Maharana et al., 2023), demonstrated in Figure 3. The afferent branch refers to the presentation of a donor antigen by host APCs. This causes changes in corneal dendritic cells which begin to express major histocompatibility complex (MHC)-II and encourage the release of proinflammatory cytokines (Yamagami et al., 2005). The effector arm refers to T cell activation and allo-reaction in lymph nodes. These sensitized T cells migrate to the cornea with CD4+ T cells recruiting additional leukocytes which mediate tissue damage and form memory T cells, enhancing the immune response seen in repeat corneal graft rejections (Niederkorn, 2007; Hori et al., 2019; Maharana et al., 2023; Yamagami et al., 2005).
Figure 3 Immunology of corneal graft rejection and the potential impact of vaccination. AC, anterior chamber; APC, antigen presenting cells; cDC, corneal dendritic cells; MIP-2, macrophage inflammatory protein 2; MHC-II, major histocompatibility comlex class II; TGF-beta, transforming growth factor-beta; TSP-1, thrombospondin 1.
The exact mechanism by which vaccination may induce corneal graft rejection is still unclear. COVID-19 vaccination is linked to other ocular pathologies such as uveitis flares (Jordan et al., 2023). Corneal graft rejection has been reported secondary to Hepatitis B, yellow fever, tetanus and influenza vaccinations but the published literature is limited to a handful of case reports (Steinemann et al., 1988; Wertheim et al., 2006; Vignapiano et al., 2022). A proposed mechanism for this association between vaccination and corneal graft rejection is that vaccination increases corneal MHC class II complex antigen expression (Steinemann et al., 1988). The systemic immune response which occurs upon receiving a vaccination may be sufficient inflammation to hinder the normal physiological immune privilege of the cornea (Maharana et al., 2023). Interestingly, our results show that there was a shorter time course between COVID-19 vaccination and rejection in older patients, which contradicts the usual increased rejection risk in younger patients due to their stronger immune response. However, although the data is not available for all these cases, it is more likely that older patients may have had more grafts or graft rejection episodes than younger patients, but there may be additional factors involved beyond the compromise of immune privilege.
The mechanism of corneal transplant rejection is likely dependent on the type of vaccination. The most common causative vaccine in the literature was BNT162b2 (Pfizer) at 33.3% of cases. However, notably, Pfizer was also the most widely used vaccine in this time period (Barouch, 2022). Most vaccines contain an attenuated or inactivated virus or bacteria, while mRNA vaccines introduce mRNA that translates into a protein on a virus’s outer membrane (Dugan and Mian, 2022). BNT162b2 (Pfizer) is a nucleoside modified mRNA vaccine that elicits a strong adaptive humoral and cellular immune response. In large scale randomized control trials participants showed raised levels of CD4+ T helper cells and inflammatory cytokines such as interferon-gamma, as well as CD8+ T cells by day 29 post-vaccination (Anderson et al., 2020; Sahin et al., 2021). These immune factors have all been implicated in the pathogenesis of corneal graft rejection. It was also suggested that there was cross-reactivity between the SARS-CoV-2 antigen and MHC-antigen complexes present in the cornea. Therefore, when an mRNA vaccine introduces a corresponding SARS-CoV-2 mRNA, this may activate and upregulate MHC-antigen complexes, thereby inducing inflammatory processes and rejection (Rajagopal and Priyanka, 2022; Kuziez et al., 2023). There is significant cross-reactivity documented between mRNA vaccines and COVID-19 variant strains suggesting non-specific antigen binding which may extend to the cornea (Melo-González et al., 2021). An analysis of the adverse events global database revealed more vaccine associated rejection events following the second dose of COVID-19 vaccination, suggesting that established antigenic sensitization leads to a larger immunological response. This analysis also noted no reported corneal graft rejection episodes following Adenovirus vector based vaccines as compared to mRNA vaccines (Singh et al., 2022).
There is yet to be a statistically significant study published documenting any vaccination definitively provoking corneal graft rejection. As corneal graft rejection is an uncommon event, part of this discrepancy may be associated with the large sample size required to ascertain a significant association, as well as changes in health-seeking behavior at the height of the COVID pandemic, which may further confound the interpretation of trends. Despite the lack of confirmed association, there is a significant perceived association both clinically and in the published literature (Lee and Huang, 2021; Lockington, 2021; Lockington et al., 2021; Singh et al., 2022; Moura-Coelho et al., 2023). It may be prudent to discuss the option of prophylaxis before vaccination, particularly in patients with known risk factors for rejection, or in “only eyes”. This must be balanced with the associated risks of topical steroid treatment including microbial keratitis and raised intraocular pressure (Kim et al., 2016). Demonstrating successful mitigation of risk through increased topical steroid use will avoid contributing to vaccine hesitancy and reassure patients that a corneal graft is not a contraindication to receiving a vaccination (Lockington, 2021). Health literacy around the clinical signs of rejection which patients may observe should remain a priority for ensuring prompt presentation and treatment.
Limitations
The primary limitation of this review is the scarcity of large-scale series, with the majority of published data correlating COVID-19 vaccination and corneal graft rejection being isolated case reports or small series. This meant there were some inconsistencies with the way data was reported or made available. Where possible, case series were included and compared with other systematic reviews. The relatively small number of original papers meant that the same data was referenced repeatedly across several review articles and systematic reviews. However, we only included original case reports/series in our analysis and excluded data which was reproduced in other reports. Moreover, there may have been papers missed in the search criteria, should the titles or abstracts not contain the keywords. However, this review provides a thorough overview of COVID-19 vaccination-associated corneal graft rejection and the possible immunological mechanisms for this. The data to date suggests strong correlation between vaccination and allograft rejection in corneal transplantation however, the evidence is not yet convincing of cause and effect. Nonetheless, since billions of COVID-19 vaccinations have been administered it is likely that in the future that more concrete data may be available and therefore more definitive conclusions in regard to the aetiology of corneal graft rejection in the post pandemic population may be defined. Whilst correlation does not necessarily imply causality in terms of COVID-19 vaccination and the rejection episode, the clear reporting of associated comorbidities and risk factors allows for these to be taken into consideration in the analysis.
Conclusion
The relationship between COVID-19 vaccination and corneal graft rejection is complex and fraught with confounding factors. It appears unlikely that a significant degree of causative relationship will be established in the literature in the near future, and keratoplasty is not a contraindication for vaccination. Early recognition of symptoms and signs of rejection by both patients and clinicians is essential to prevent vision loss and graft failure. Clinician discretion and patient concerns with respect to vaccination are required when considering topical steroid prophylaxis in high-risk corneal graft patients. Further investigation into the mechanism of vaccination-associated corneal graft rejection may provide additional insight in the future.
Author contributions
NA: Writing – original draft. JZ: Writing – review & editing. CM: Methodology, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Publication of this paper was funded by The University of Auckland.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abousy, M., Bohm, K., Prescott, C., Bonsack, J. M., Rowhani-Farid, A., Eghrari, A. O. (2021). Bilateral EK rejection after COVID-19 vaccine. Eye Contact Lens 47, 625–628. doi: 10.1097/ICL.0000000000000840
Al-Dwairi, R. A., Aleshawi, A., Adi, S., Abu-Zreig, L. (2022). Reactivation of herpes simplex keratitis on a corneal graft following SARS-coV-2 mRNA vaccination. Med. Arch. Sarajevo Bosnia Herzeg. 76, 146–148. doi: 10.5455/medarh.2022.76.146-148
Alhumaid, S., Rabaan, A. A., Dhama, K., Yong, S. J., Nainu, F., Hajissa, K., et al. (2022). Solid organ rejection following SARS-coV-2 vaccination or COVID-19 infection: A systematic review and meta-analysis. Vaccines 10, 1289. doi: 10.3390/vaccines10081289
Alio, J. L., Montesel, A., El Sayyad, F., Barraquer, R. I., Arnalich-Montiel, F., Alio Del Barrio, J. L. (2021). Corneal graft failure: an update. Br. J. Ophthalmol. 105, 1049–1058. doi: 10.1136/bjophthalmol-2020-316705
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., et al. (2020). Safety and immunogenicity of SARS-coV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 383, 2427–2438. doi: 10.1056/NEJMoa2028436
Balidis, M., Mikropoulos, D., Gatzioufas, Z., de Politis, P. B., Sidiropoulos, G., Vassiliadis, V. (2021). Acute corneal graft rejection after anti-severe acute respiratory syndrome-coronavirus-2 vaccination: A report of four cases. Eur. J. Ophthalmol. 33, 11206721211064033. doi: 10.1177/11206721211064033
Barouch, D. H. (2022). Covid-19 vaccines — Immunity, variants, boosters. N. Engl. J. Med. 387, 1011–1020. doi: 10.1056/NEJMra2206573
Bizimungu, C., Sabbe, M., Wuillaume, F., Hamdani, J., Koch, P., Dogne, J.-M. (2023). Challenges in assessing COVID-19 vaccines safety signals-the case of chAdOx1 nCoV-19 vaccine and corneal graft rejection. Vaccines 11, 954. doi: 10.3390/vaccines11050954
Bron, A. J., Tripathi, R. C., Tripathi, B. J., Wolff, E. (1997). Wolff’s anatomy of the eye and orbit. 8th ed (London Weinheim: Chapman & Hall Medical).
Busin, M., Zauli, G., Pellegrini, M., Virgili, G., Yu, A. C. (2022). COVID-19 vaccination may not increase rates of corneal graft rejection. Cornea 41, 1536–1538. doi: 10.1097/ICO.0000000000003101
Crawford, A. Z., Patel, D. V., McGhee, C. N. (2013). A brief history of corneal transplantation: From ancient to modern. Oman J. Ophthalmol. 6, S12–S17. doi: 10.4103/0974-620X.122289
Crnej, A., Khoueir, Z., Cherfan, G., Saad, A. (2021). Acute corneal endothelial graft rejection following COVID-19 vaccination. J. Fr. Ophtalmol. 44, e445–e447. doi: 10.1016/j.jfo.2021.06.001
Dugan, S. P., Mian, S. I. (2022). Impact of vaccination on keratoplasty. Curr. Opin. Ophthalmol. 33, 296–305. doi: 10.1097/ICU.0000000000000855
Eduarda Andrade E Andrade, M., Rodrigues, J. C., Junior, E. F., de Lima, M. H. C. (2022). Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19. Indian J. Ophthalmol. 70, 3134–3136. doi: 10.4103/ijo.IJO_1021_22
Forshaw, T. R. J., Jørgensen, C., Kyhn, M. C., Cabrerizo, J. (2022). Acute bilateral descemet membrane endothelial keratoplasty graft rejection after the BNT162b2 mRNA COVID-19 vaccine. Int. Med. Case Rep. J. 15, 201–204. doi: 10.2147/IMCRJ.S362698
Fujio, K., Sung, J., Nakatani, S., Yamamoto, K., Iwagami, M., Fujimoto, K., et al. (2022). Characteristics and clinical ocular manifestations in patients with acute corneal graft rejection after receiving the COVID-19 vaccine: A systematic review. J. Clin. Med. 11, 4500. doi: 10.3390/jcm11154500
Ghiasian, L., Pourmousa, Z., Hadi, Y., Abdolalizadeh, P. (2023). Corneal allograft endothelial rejection after sinopharm COVID-19 vaccination; report of six cases. Semin. Ophthalmol. 38, 565–571. doi: 10.1080/08820538.2023.2169579
Gonzalez-Rey, E., Chorny, A., Delgado, M. (2007). Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 7, 52–63. doi: 10.1038/nri1984
Gouvea, L., Slomovic, A. R., Chan, C. C. (2022). “Smoldering” Rejection of keratolimbal allograft. Cornea 41, 651–653. doi: 10.1097/ICO.0000000000002978
Haseeb, A. A., Solyman, O., Abushanab, M. M., Abo Obaia, A. S., Elhusseiny, A. M. (2022). Ocular complications following vaccination for COVID-19: A one-year retrospective. Vaccines 10, 342. doi: 10.3390/vaccines10020342
Hori, J., Yamaguchi, T., Keino, H., Hamrah, P., Maruyama, K. (2019). Immune privilege in corneal transplantation. Prog. Retin. Eye Res. 72, 100758. doi: 10.1016/j.preteyeres.2019.04.002
Huang, L.-Y., Chiang, C.-C., Li, Y.-L., Lai, H.-Y., Hsieh, Y.-C., Wu, Y.-H., et al. (2022). Corneal complications after COVID-19 vaccination: A systemic review. J. Clin. Med. 11, 6828. doi: 10.3390/jcm11226828
Jordan, C. A., Townend, S., Allen, N., Sims, J., McGhee, C. N. J., Niederer, R. L. (2023). Navigating coronavirus disease 2019 vaccination and uveitis. Ophthalmology 130, 501–508. doi: 10.1016/j.ophtha.2022.12.013
Kim, B., Meyer, J., Brookes, N., Moffatt, S., Twohill, H., Pendergrast, D., et al. (2016). New Zealand trends in corneal transplantation over the 25 years 1991–2015. Br. J. Ophthalmol. 101, 1–5. doi: 10.1136/bjophthalmol-2016-309021
Kumari, S., Anand, R., Sambyal, B., Singh, Y., Rangappa, P., Jha, S. K. (2022). Ocular adverse effects of COVID-19 vaccines: A systematic review. J. Fam. Med. Prim. Care 11, 5041–5054. doi: 10.4103/jfmpc.jfmpc_747_22
Kuziez, L., Eleiwa, T. K., Chauhan, M. Z., Sallam, A. B., Elhusseiny, A. M., Saeed, H. N. (2023). Corneal adverse events associated with SARS-coV-2/COVID-19 vaccination: A systematic review. Vaccines 11, 166. doi: 10.3390/vaccines11010166
Lee, Y.-K., Huang, Y.-H. (2021). Ocular manifestations after receiving COVID-19 vaccine: A systematic review. Vaccines 9, 1404. doi: 10.3390/vaccines9121404
Lockington, D. (2021). Keratoplasty rejection risk associated with recent vaccination—The pragmatic approach. Cornea 40, 13–16. doi: 10.1097/ICO.0000000000002818
Lockington, D., Lee, B., Jeng, B. H., Larkin, D. F. P., Hjortdal, J. (2021). Survey of corneal surgeons’ Attitudes regarding keratoplasty rejection risk associated with vaccinations. Cornea Publish Ahead Print. doi: 10.1097/ICO.0000000000002662
Lu, L. M., Boyle, A. B., Niederer, R. L., Brookes, N. H., McGhee, C. N. J., Patel, D. V. (2019). Repeat corneal transplantation in Auckland, New Zealand: Indications, visual outcomes and risk factors for repeat keratoplasty failure. Clin. Experiment. Ophthalmol. 47, 987–994. doi: 10.1111/ceo.13581
Maharana, P. K., Mandal, S., Kaweri, L., Sahay, P., Lata, S., Asif, M. I., et al. (2023). Immunopathogenesis of corneal graft rejection. Indian J. Ophthalmol. 71, 1733–1738. doi: 10.4103/IJO.IJO_2866_22
Marziali, E., Pasqualetti, R., Bacci, G., de Libero, C., Caputo, R. (2022). Acute rejection following COVID-19 vaccination in penetrating keratoplasty in a young male - A case report and review of literature. Ocul. Immunol. Inflamm. 31, 1226–1229. doi: 10.1080/09273948.2022.2106248
Mathieu, E., Ritchie, H., Rodés-Guirao, L., Appel, C., Giattino, C., Hasell, J., et al. (2020). Coronavirus pandemic (COVID-19). Published online at OurWorldInData.org. Retrieved from: https://ourworldindata.org/coronavirus [Online Resource].
Melo-González, F., Soto, J. A., González, L. A., Fernández, J., Duarte, L. F., Schultz, B. M., et al. (2021). Recognition of variants of concern by antibodies and T cells induced by a SARS-coV-2 inactivated vaccine. Front. Immunol. 12. doi: 10.3389/fimmu.2021.747830
Mohammadzadeh, M., Hooshmandi, S., Jafari, M., Hassanpour, K. (2022). Presumably corneal graft rejection after COVID-19 vaccination. Case Rep. Ophthalmol. 13, 562–569. doi: 10.1159/000525631
Molero-Senosiain, M., Houben, I., Savant, S., Savant, V. (2022). Five cases of corneal graft rejection after recent COVID-19 vaccinations and a review of the literature. Cornea 41, 669–672. doi: 10.1097/ICO.0000000000002980
Moura-Coelho, N., Cunha, J. P., Papa-Vettorazzi, R., Gris, Ó., Güell, J. L. (2023). Acute corneal allograft rejection following SARS-CoV-2 vaccination-A systematic review. Acta Ophthalmol. (Copenh.) 101, e1–e13. doi: 10.1111/aos.15211
Msemburi, W., Karlinsky, A., Knutson, V., Aleshin-Guendel, S., Chatterji, S., Wakefield, J. (2023). The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature 613, 130–137. doi: 10.1038/s41586-022-05522-2
Nahata, H., Nagaraja, H., Shetty, R. (2022). A case of acute endothelial corneal transplant rejection following immunization with ChAdOx1 nCoV-19 coronavirus vaccine. Indian J. Ophthalmol. 70, 1817–1818. doi: 10.4103/ijo.IJO_66_22
Niederkorn, J. Y. (2006). See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat. Immunol. 7, 354–359. doi: 10.1038/ni1328
Niederkorn, J. Y. (2007). Immune mechanisms of corneal allograft rejection. Curr. Eye Res. 32, 1005–1016. doi: 10.1080/02713680701767884
Nioi, M., D’Aloja, E., Fossarello, M., Napoli, P. E. (2021). Dual corneal-graft rejection after mrna vaccine (Bnt162b2) for covid-19 during the first six months of follow-up: Case report, state of the art and ethical concerns. Vaccines 9, 1–9. doi: 10.3390/vaccines9111274
Panda, A., Vanathi, M., Kumar, A., Dash, Y., Priya, S. (2007). Corneal graft rejection. Surv. Ophthalmol. 52, 375–396. doi: 10.1016/j.survophthal.2007.04.008
Park, J. M., Lee, J. H., Hwang, J. H., Kang, M.-J. (2023). Corneal Graft Rejection after Vaccination against COVID-19: A Case Report. Korean J. Ophthalmol. KJO 37, 85–87. doi: 10.3341/kjo.2022.0105
Parmar, D. P., Garde, P. V., Shah, S. M., Bhole, P. K. (2021). Acute graft rejection in a high-risk corneal transplant following COVID-19 vaccination: A case report. Indian J. Ophthalmol. 69, 3757–3758. doi: 10.4103/ijo.IJO_2515_21
Phylactou, M., Li, J.-P. O., Larkin, D. F. P. (2021). Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine. Br. J. Ophthalmol. 105, 893–896. doi: 10.1136/bjophthalmol-2021-319338
Rajagopal, R., Priyanka, T. M. (2022). Stromal rejection in penetrating keratoplasty following COVID-19 vector vaccine (Covishield) - A case report and review of literature. Indian J. Ophthalmol. 70, 319–321. doi: 10.4103/ijo.IJO_2539_21
Rallis, K. I., Ting, D. S. J., Said, D. G., Dua, H. S. (2022). Corneal graft rejection following COVID-19 vaccine. Eye Lond. Engl. 36, 1319–1320. doi: 10.1038/s41433-021-01671-2
Ravichandran, S., Natarajan, R. (2021). Corneal graft rejection after COVID-19 vaccination. Indian J. Ophthalmol. 69, 1953–1954. doi: 10.4103/ijo.IJO_1028_21
Roberts, H. W., Wilkins, M. R., Malik, M., Talachi-Langroudi, M., Myerscough, J., Pellegrini, M., et al. (2022). A lack of an association between COVID-19 vaccination and corneal graft rejection: results of a large multi-country population based study. Eye Lond. Engl. 35, 1–4. doi: 10.1038/s41433-022-02341-7
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., et al. (2021). BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572–577. doi: 10.1038/s41586-021-03653-6
Sen, M., Honavar, S. G. (2021). After the storm: ophthalmic manifestations of COVID-19 vaccines. Indian J. Ophthalmol. 69, 3398–3420. doi: 10.4103/ijo.IJO_2824_21
Shah, A. P., Dzhaber, D., Kenyon, K. R., Riaz, K. M., Ouano, D. P., Koo, E. H. (2022). Acute corneal transplant rejection after COVID-19 vaccination. Cornea 41, 121–124. doi: 10.1097/ICO.0000000000002878
Simão, M. F., Kwitko, S. (2022). Corneal graft rejection after inactivated SARS-coV-2 vaccine: case report. Cornea 41, 502–504. doi: 10.1097/ICO.0000000000002970
Singh, R. B., Li, J., Parmar, U. P. S., Jeng, B. H., Jhanji, V. (2022). Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis. Br. J. Ophthalmol. 0, 322512. doi: 10.1136/bjo-2022-322512
Steinemann, T. L., Koffler, B. H., Jennings, C. D. (1988). Corneal allograft rejection following immunization. Am. J. Ophthalmol. 106, 575–578. doi: 10.1016/0002-9394(88)90588-0
Streilein, J. W. (2003). Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3, 879–889. doi: 10.1038/nri1224
Swarup, R., Mehta, S. (2023). DALK rejection following vaccination against SARS-CoV-2: 2 case reports. Eur. J. Ophthalmol. 0, 11206721231158672. doi: 10.1177/11206721231158672
Vignapiano, R., Vicchio, L., Favuzza, E., Cennamo, M., Mencucci, R. (2022). Corneal graft rejection after yellow fever vaccine: A case report. Ocul. Immunol. Inflamm. 30, 1207–1210. doi: 10.1080/09273948.2020.1870146
Wang, M. T. M., Niederer, R. L., McGhee, C. N. J., Danesh-Meyer, H. V. (2022). COVID-19 vaccination and the eye. Am. J. Ophthalmol. 240, 79–98. doi: 10.1016/j.ajo.2022.02.011
Wasser, L. M., Roditi, E., Zadok, D., Berkowitz, L., Weill, Y. (2021). Keratoplasty rejection after the BNT162b2 messenger RNA vaccine. Cornea 40, 1070. doi: 10.1097/ICO.0000000000002761
Wertheim, M. S., Keel, M., Cook, S. D., Tole, D. M. (2006). Corneal transplant rejection following influenza vaccination. Br. J. Ophthalmol. 90, 925–925. doi: 10.1136/bjo.2006.093187
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324, 782. doi: 10.1001/jama.2020.12839
Yamagami, S., Hamrah, P., Zhang, Q., Liu, Y., Huq, S., Dana, M. R. (2005). Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation. Mol. Vis. 11, 632–640.
Yin, J. (2021). Advances in corneal graft rejection. Curr. Opin. Ophthalmol. 32, 331–337. doi: 10.1097/ICU.0000000000000767
Yu, S., Ritterband, D. C., Mehta, I. (2022). Acute corneal transplant rejection after severe acute respiratory syndrome coronavirus 2 mRNA-1273 vaccination. Cornea 41, 257–259. doi: 10.1097/ICO.0000000000002886
Keywords: COVID-19, vaccination, cornea, keratoplasty, rejection
Citation: Allen NE, Zhang J and McGhee CNJ (2023) COVID-19 vaccination and corneal allograft rejection- a review. Front. Cell. Infect. Microbiol. 13:1307655. doi: 10.3389/fcimb.2023.1307655
Received: 05 October 2023; Accepted: 23 November 2023;
Published: 15 December 2023.
Edited by:
Xinyuan Zhang, Capital Medical University, ChinaReviewed by:
Haiyue Xu, The University of Texas at Austin, United StatesMajid Moshirfar, University of Utah, United States
Copyright © 2023 Allen, Zhang and McGhee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Charles N. J. McGhee, Yy5tY2doZWVAYXVja2xhbmQuYWMubno=